List of CRISPR Therapeutics patents

Patents where

Current Assignee

Name

CRISPR Therapeutics

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 11566230 Universal donor cells	Patent 11566230 was granted and assigned to CRISPR Therapeutics on January, 2023 by the United States Patent and Trademark Office.	CRISPR Therapeutics	CRISPR Therapeutics	United States Patent and Trademark Office	11566230	January 31, 2023
‌ US Patent 11459372 Gene-edited natural killer cells		CRISPR Therapeutics	CRISPR Therapeutics	United States Patent and Trademark Office	11459372	October 4, 2022
‌ US Patent 11559588 Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disorders	Patent 11559588 was granted and assigned to CRISPR Therapeutics on January, 2023 by the United States Patent and Trademark Office.	CRISPR Therapeutics	CRISPR Therapeutics	United States Patent and Trademark Office	11559588	January 24, 2023
‌ US Patent 11591381 Gene-edited natural killer cells	Patent 11591381 was granted and assigned to CRISPR Therapeutics on February, 2023 by the United States Patent and Trademark Office.	CRISPR Therapeutics	CRISPR Therapeutics	United States Patent and Trademark Office	11591381	February 28, 2023
‌ US Patent 11497773 Genetically engineered t cells with regnase-1 and/or TGFBRII disruption have improved functionality and persistence	Patent 11497773 was granted and assigned to CRISPR Therapeutics on November, 2022 by the United States Patent and Trademark Office.	CRISPR Therapeutics	CRISPR Therapeutics	United States Patent and Trademark Office	11497773	November 15, 2022
‌ US Patent 11298378 Materials and methods for engineering cells and uses thereof in immuno-oncology	Patent 11298378 was granted and assigned to CRISPR Therapeutics on April, 2022 by the United States Patent and Trademark Office.	CRISPR Therapeutics	CRISPR Therapeutics	United States Patent and Trademark Office	11298378	April 12, 2022
‌ US Patent 11578309 Universal donor cells	Patent 11578309 was granted and assigned to CRISPR Therapeutics on February, 2023 by the United States Patent and Trademark Office.	CRISPR Therapeutics	CRISPR Therapeutics	United States Patent and Trademark Office	11578309	February 14, 2023
‌ US Patent 11407997 Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders	Patent 11407997 was granted and assigned to CRISPR Therapeutics on August, 2022 by the United States Patent and Trademark Office.	CRISPR Therapeutics	CRISPR Therapeutics	United States Patent and Trademark Office	11407997	August 9, 2022
‌ US Patent 11433103 Universal donor cells	Patent 11433103 was granted and assigned to CRISPR Therapeutics on September, 2022 by the United States Patent and Trademark Office.	CRISPR Therapeutics	CRISPR Therapeutics	United States Patent and Trademark Office	11433103	September 6, 2022
‌ US Patent 11471491 Materials and methods for engineering cells and uses thereof in immuno-oncology		CRISPR Therapeutics	CRISPR Therapeutics	United States Patent and Trademark Office	11471491	October 18, 2022
‌ US Patent 11434505 Universal donor cells	Patent 11434505 was granted and assigned to CRISPR Therapeutics on September, 2022 by the United States Patent and Trademark Office.	CRISPR Therapeutics	CRISPR Therapeutics	United States Patent and Trademark Office	11434505	September 6, 2022
‌ US Patent 11622977 Materials and methods for engineering cells and uses thereof in immuno-oncology	Patent 11622977 was granted and assigned to CRISPR Therapeutics on April, 2023 by the United States Patent and Trademark Office.	CRISPR Therapeutics	CRISPR Therapeutics	United States Patent and Trademark Office	11622977	April 11, 2023
‌ US Patent 11389481 Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19	Patent 11389481 was granted and assigned to CRISPR Therapeutics on July, 2022 by the United States Patent and Trademark Office.	CRISPR Therapeutics	CRISPR Therapeutics	United States Patent and Trademark Office	11389481	July 19, 2022
‌ US Patent 11473060 Compositions and methods for differentiating stem cells into NK cells		CRISPR Therapeutics	CRISPR Therapeutics	United States Patent and Trademark Office	11473060	October 18, 2022
‌ US Patent 11071755 Materials and methods for engineering cells and uses thereof in immuno-oncology	Patent 11071755 was granted and assigned to CRISPR Therapeutics on July, 2021 by the United States Patent and Trademark Office.	CRISPR Therapeutics	CRISPR Therapeutics	United States Patent and Trademark Office	11071755	July 27, 2021
‌ US Patent 11166985 Materials and methods for engineering cells and uses thereof in immuno-oncology	Patent 11166985 was granted and assigned to CRISPR Therapeutics on November, 2021 by the United States Patent and Trademark Office.	CRISPR Therapeutics	CRISPR Therapeutics	United States Patent and Trademark Office	11166985	November 9, 2021
‌ US Patent 11254912 Methods and compositions for treating cancer	Patent 11254912 was granted and assigned to CRISPR Therapeutics on February, 2022 by the United States Patent and Trademark Office.	CRISPR Therapeutics	CRISPR Therapeutics	United States Patent and Trademark Office	11254912	February 22, 2022
‌ US Patent 11135247 Materials and methods for engineering cells and uses thereof in immuno-oncology	Patent 11135247 was granted and assigned to CRISPR Therapeutics on October, 2021 by the United States Patent and Trademark Office.	CRISPR Therapeutics	CRISPR Therapeutics	United States Patent and Trademark Office	11135247	October 5, 2021
‌ US Patent 11191783 Materials and methods for engineering cells and uses thereof in immuno-oncology	Patent 11191783 was granted and assigned to CRISPR Therapeutics on December, 2021 by the United States Patent and Trademark Office.	CRISPR Therapeutics	CRISPR Therapeutics	United States Patent and Trademark Office	11191783	December 7, 2021
‌ US Patent 11332760 Compositions and methods for genomic editing by insertion of donor polynucleotides		CRISPR Therapeutics	CRISPR Therapeutics	United States Patent and Trademark Office	11332760	May 17, 2022
‌ US Patent 10881689 Materials and methods for engineering cells and uses thereof in immuno-oncology	Patent 10881689 was granted and assigned to CRISPR Therapeutics on January, 2021 by the United States Patent and Trademark Office.	CRISPR Therapeutics	CRISPR Therapeutics	United States Patent and Trademark Office	10881689	January 5, 2021
‌ US Patent 11564997 Materials and methods for treatment of friedreich ataxia and other related disorders	Patent 11564997 was granted and assigned to CRISPR Therapeutics on January, 2023 by the United States Patent and Trademark Office.	CRISPR Therapeutics	CRISPR Therapeutics	United States Patent and Trademark Office	11564997	January 31, 2023
‌ US Patent 11649438 Methods and compositions for treating cancer	Patent 11649438 was granted and assigned to CRISPR Therapeutics on May, 2023 by the United States Patent and Trademark Office.	CRISPR Therapeutics	CRISPR Therapeutics	United States Patent and Trademark Office	11649438	May 16, 2023
‌ US Patent 10857184 Materials and methods for engineering cells and uses thereof in immuno-oncology	Patent 10857184 was granted and assigned to CRISPR Therapeutics on December, 2020 by the United States Patent and Trademark Office.	CRISPR Therapeutics	CRISPR Therapeutics	United States Patent and Trademark Office	10857184	December 8, 2020
‌ US Patent 10736919 Materials and methods for engineering cells and uses thereof in immuno-oncology	Patent 10736919 was granted and assigned to CRISPR Therapeutics on August, 2020 by the United States Patent and Trademark Office.	CRISPR Therapeutics	CRISPR Therapeutics	United States Patent and Trademark Office	10736919	August 11, 2020

Results per page:

45 results

0 selected

45 results

0 selected